Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

0(0%)

Results Posted

50%(3 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_4

29%

Ph phase_3

43%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 3Large-scale testing

3(60.0%)

Phase 4Post-market surveillance

2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(1)

Detailed Status

Completed6

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 4

Trials by Phase

Phase 33 (60.0%)

Phase 42 (40.0%)

Trials by Status

terminated114%

completed686%

Recent Activity

0 active trials

Showing 5 of 7

completed

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520

completedphase_3

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

NCT00307047

terminatedphase_4

SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

NCT00917163

completed

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

NCT00631228

completedphase_3

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

NCT00180479

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT00676520

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

Completed

NCT00307047Phase 3

SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

Completed

NCT00917163Phase 4

SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent

Terminated

NCT00631228

XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study

Completed

NCT00180479Phase 3

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Completed

NCT00180310Phase 3

SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System

Completed

NCT00402272Phase 4

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe

Completed

All 7 trials loaded

Drug Details

Intervention Type: DEVICE
Total Trials: 7